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& G2 (2)). Dice similarity coefficients (DSC) were used to compare G1 
and G2 spatial similarity. G1 and G2 defined structures were 
subsequently analysed for planned dose discrepancy. 
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Results: Differences in G1 and G2 delineation guidelines reported DSC 
values less than 0.5, indicating poor spatial correlation- SPCM 
(DSC=0.09±0.09, range of 0.02-0.22), MPCM (DSC=0.47±0.16, 
range:0.26 to 0.63), IPCM (DSC=0.34±0.12, range: 0.19 to 0.49), CP 
(DSC=0.33±0.12,range: 0.12 to 0.41), and OI (DSC=0.15±0.13, range: 0 
to 0.31). This difference in delineation led to dose differences for 
each structure (Dmean), shown inTable I, with some structures 
impacted by up to 13.9 %. Such variation is indicative of the variable 
proximity of the pharyngeal axis to areas of steep dose heterogeneity. 
In general, the range of per-structure dose differences across all 
patients was large, showing that indicated complication probability 
can be highly dependent upon which guideline is chosen for clinical 
use. 
Table 1. Dose difference of Dmean between structures delineated 
with G1 and G2 guidelines 
  
Conclusions: Whilst this study reported varying degrees of correlation 
between planned dosimetry and spatial incongruity, it highlights the 
potential of dosimetric variability with inconsistent delineation 
guidelines and the mandate to investigate with a larger patient cohort 
across multiple critical structures. When critical structures lie in close 
proximity to areas of steep dose heterogeneity, delineation disparity 
and subsequent dose discrepancy is of greater significance. Integrity 
of future DVO data demands a consensus on delineation guidelines to 
ensure recommendations are robust in clinical practice. 
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Purpose/Objective: To evaluate the effect of post-radiation adjuvant 
chemotherapy with oral tegafur-uracil in patients with high-risk 
nasopharygeal carcinoma (NPC) after combined chemoradiotherapy. 
Materials and Methods: Our definition of high-risk NPC included 
patients with 1) neck node > 6 cm; 2) supraclavicular node metastasis; 
3) skull base destruction/intracranial invasion plus multiple nodes 
metastasis; or 4) multiple neck nodes metastasis with one of nodal 
size > 4 cm. One hundred and sixty-three high-risk NPC patients 
finished full-course of concurrent chemoradiotherapy or neoadjuvant 
chemotherapy plus radiotherapy. Post-radiation adjuvant 
chemotherapy with oral tegafur-uracil (200 mg twice daily) for 12 
months was recommended to evaluate its impact on subsequent tumor 
relapse. One hundred and forty-one patients agreed to receive 
adjuvant oral tegafur-uracil. Twenty-two patients who refused 
adjuvant chemotherapy were served as a control. 
Results: After a median follow-up of 38 months, 32 of 141 (22.7%) 
patients with adjuvant tegafur-uracil developed tumor relapse later, 
whereas 59.1% (13/22) patients without adjuvant tegafur-uracil had 
tumor relapse. The progression-free survival rates were significantly 
higher in patients with adjuvant tegafur-uracil than those without 
adjuvant tegafur-uracil (P<0.0001). The adjuvant chemotherapy of 
tegafur-uracil was well-tolerated with no grade 3/4 toxicity. 
Conclusions: Post-radiation adjuvant chemotherapy with oral tegafur-
uracil for 12 months significantly reduced the relapse rate in high-risk 
NPC patients.  
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Purpose/Objective: A four-dimensional (4D) cone-beam CT (CBCT) is 
widely implemented in the precise radiation therapy of lung cancer 
treatment.In this study, we present a novel verification system for an 
image-guided radiation therapy (IGRT) by using in-treatment 4D CBCT 
acquired during Volumetric Modulated Arc Therapy (VMAT). 
Materials and Methods: A Stereotactic Body Radiation Therapy (SBRT) 
for lung cancer patient was performed by Elekta Synergy with a single-
arc VMAT. During the beam delivery, cone-beam projection images 
were sequentially acquired. A respiratory signal was reproduced by an 
image-based phase recognition technique computed with a normalized 
cross correlation between adjacent projections.Then, in-treatment 4D 
CBCT with four phase bins was reconstructed by in-house software and 
the CBCT sets were exported into the treatment planning system 
(TPS). After a registration of the CBCT center with the isocenter 
position in the corresponding treatment plan, the tumor location 
visualized in the CBCT for each phase was compared with that in the 
treatment plan. To see how this system works well, in particular, the 
center-of-mass (COM) of gross tumor volume (GTV) for maximum 
inhalation and exhalation for 10 patients was compared with those 
estimated by the planning CT. 
Results: The differences in maximum inhalation were 0.3 ± 1.3 mm, 
0.2 ± 1.7 mm, -0.7 ± 3.1 mm for the LR, AP, and CC directions, 
respectively,whereas the differences in maximum exhalation were 0.1 
± 1.3 mm, -0.4 ± 1.8 mm, -0.1 ± 1.9 mm for the LR,AP, and CC 
directions, respectively. 
Conclusions: In-treatment 4D CBCT is a direct method for 
quantitatively assessing the intrafractional location of a moving 
target. It was feasible to verify the tumor location during actual beam 
delivery with the system developed by using in-treatment 4D CBCT.  
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Purpose/Objective: Three–dimensional non-coplanar conformal 
radiotherapy (3-DNCCRT) has recently been considered promising for 
the treatment of stage I non-small cell lung cancer (NSCLC). Usually, 
it is performed in the form of SBRT using 10 – 20Gy fraction dose. 
However, this method is considered to be contraindicated for so-
called central tumors because of the toxicity of serial organs, such as 
bronchus, large vessels, etc. We have been treating these tumors with 
relatively small fraction dose (usually 3Gy) keeping BED10 at the 
similar level to that of SBRT. In this study, we analyzed our 10-year 
results. 
Materials and Methods: Eligibility criteria were as follows: maximum 
tumor diameter not greater than 5cm, PS between 0 and 2, and no 
limitation regarding age and pulmonary function. Radiotherapy was 
given with 6MV photon beam by fixed 10 non-coplanar conformal 
beams to a total dose of 75Gy in 25 fractionsin 5 weeks. Irradiation 
was aiming at the ITV with proper margins. No ENI was given. Between 
Jan. 2002 and Dec. 2010, 111 eligible cases were treated. Age ranged 
from 53 to 93 (median 78). The male/female ratio was 80/31. There 
were 64T1 tumors and 47 T2. Twenty-four tumors were sqcca, 71 
adenoca, and 16 others.There were 92 inoperable cases (83%), among 
them poor pulmonary function was in 66 (59%), and 19 operable cases, 
who refused operation. The average tumor size was 3.0 cm (range; 1.2 
to 5.0 cm). There were 102 PS 1 and 9 PS 2 cases. Among the entire 
cases, 46 cases were central tumors and the other 65 were peripheral 
tumors. Median follow-up period was 46 months.  
Results: Three- and 5-year local control rate (LC), overall survival 
rate (OS), cause-specific survival rate, and relapse-free survival rate 
for overall cases were, 85% and 85%, 67% and 50%, 79% and 65%, and 
56% and 41%, respectively. Three-year LC and OS for T1 and T2 cases 
were 87%, 66%, and 87%, 69%, respectively (n.s.). Three-year LC and 
OS for central and peripheral tumors were 85%, 70%, and 86%, 66%, 
respectively (n.s.). Three- and 5-year OS for operable and inoperable 
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cases were 89%, 89%, and 65%, 43%, respectively (p=0.055). Patterns 
of initial relapse were, local in 11 cases, pleural in 5, nodal in 8, and 
distant in 13. There were 7 Grade 3 pulmonary toxicities (6%), but 
there were no severe adverse effects concerning serial organs. 
Conclusions: Three-DNCCRT for stage I non-small cell lung cancer has 
been safe and effective for not only inoperable but also operable 
cases, and equally effective for peripheral and central tumors, and T1 
and T2 tumors. Our treatment might be an alternative to SBRT 
especially central tumors and T2 tumors, which the results of SBRT 
have not been satisfactory. 
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Purpose/Objective: Locally advanced non-small cell lung cancers 
(NSCLC) are typically treated with 60 to 66 Gy in 2 Gy fractions. Local 
control for this treatment is poor, but it could potentially be improved 
by increasing dose to the more therapy resistant areas,e.g., based on 
the SUV uptake values on the pre-treatment FDG-PET scan. This is the 
dose painting by numbers (DPBN) approach, which intrinsically does 
not allow a conventional PTV margin. This study investigates the 
influence of random and systematic errors on target dose coverage 
with DPBN, in terms of difference between dose to 99% of GTV volume 
(Δ99) when geometric errors are considered. For example, Δ99 = -10 
Gy means that, for 99% of the target volume, the dose delivered is 
decreased by no more than 10 Gy compared to the planned dose. 
Materials and Methods: 9 DPBN plans of stage II/III NSCLC patients 
were considered; a minimum dose of 66 Gy at 2-Gy fractions was 
prescribed to the entire CTV with a boost dose to the high SUV areas 
within the primary GTV, using a non-uniform dose prescription linear 
with the underlying FDG PET SUV. The boost dose was escalated up to 
130 Gy (in 33 fractions) or until the dose limiting constraint of an 
organ at risk was reached. Then, using Monte Carlo methods, a 
probabilistic evaluation of dose endpoints at 90% confidence was 
performed considering 8 different combinations of systematic (Σ) and 
random (σ) geometric uncertainties, taken as standard deviations 
identical in x, y and z as: (Σ,σ) = (5,2); (4,2); (3,2); (2,2); (3,4); (3,3); 
(2,3); and (1,2). 
Results: The impact of geometric errors on the ability to paint dose is 




The evaluation showed a clear dependence of Δ99 on systematic 
errors (Fig. 1); the influence of random errors was less pronounced. 
The effects of the uncertainties are shifted and smoothed dose peaks; 
indeed the largest differences between planned and delivered dose 
occur where the dose or its gradient are high. 
  
  
Conclusions: A probabilistic evaluation of 9 DPBN plans showed that 
geometric uncertainties should be taken into account before 
approving the plans for treatment, otherwise significant hidden 
discrepancies between prescribed and delivered dose distributions will 
occur. The discrepancies become more acceptable when the 
systematic errors become small (Σ < 2mm), which strongly suggests 
that DPBN should be paired with an accurate IGRT. Probabilistic 
optimization, taking uncertainties into account also at the planning 
stage, might intrinsically mitigate the reported issues. 
